Renal transplant remains the treatment of choice for end-stage renal disease.1 Unfortunately, long-term graft failure rates are unsatisfactory. One potential therapy is fingolimod (FTY720), a new immunomodulator that reduces lymphocyte recirculation from lymphoid tissue to blood and peripheral tissues.2 We describe a renal transplant recipient in a phase IIIb clinical trial of fingolimod who developed cystoid macular edema (CME).
Saab G, Almony A, Blinder KJ, Schuessler R, Brennan DC. Reversible Cystoid Macular Edema Secondary to Fingolimod in a Renal Transplant Recipient. Arch Ophthalmol. 2008;126(1):140–141. doi:10.1001/archophthalmol.2007.23
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.